Akavia - instructions for use, dose, side effects, contraindications

Active substanceSodium RibonucleateSodium Ribonucleate

Similar drugsTo uncover

lyophilizate inwards

Dosage form: & nbsplyophilizate for the preparation of a suspension for oral administration

Composition:One bottle contains:

active substance: sodium ribonucleate - 6.00 mg;

Excipients: sodium chloride - 5,10 mg, phosphagidylcholine (Lipoid C 100) - 124.77 mg, cholesterol-13.73 mg, alpha-tocopherol acetate (vitamin E acetate) - 1.70 mg, lactose monohydrate - 138.70 mg .

Description:

Powder or porous mass of white or white with a yellowish hue. It is allowed to flake, complete or partial, from the surface of the glass of the vial to form a tabloid-like shape. Hygroscopic.

Pharmacotherapeutic group:Immunostimulating agent

ATX: & nbsp

L.03.A Cytokines and immunomodulators

Pharmacodynamics:

The drug AKAVIA® is the inducer of interferon synthesis, the active principle of which double-stranded RNA upon introduction into the body induces the formation of endogenous interferons: alpha, beta and gamma, which at the intracellular level inhibit the reproduction of viruses.

AKAVIA® stimulates the phagocytic activity of neutrophils and macrophages, activates T-lymphocytes and natural killer cells. Normalizes the balance between subpopulations of T-helper and T-suppressor cells.

Pharmacokinetics:

The maximum concentration of serum interferon is recorded 9 hours after oral administration of the drug and is 201.8 IU / ml. Further decrease in the concentration of interferon: up to 124.8 IU / ml by 12 hours and to 83.2 IU / ml to 24 hours after taking the drug. Metabolism is carried out in the liver; is excreted mainly through the kidneys.

Indications:

Complex therapy of recurrent urogenital herpetic infection in adults.

Contraindications:

- Children and adolescence (up to 18 years);

- elderly age;

- Hepatic and / or renal insufficiency;

- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

- pregnancy and the period of breastfeeding;

- Hypersensitivity to the active or auxiliary components of the drug.

Carefully:

In diseases of the thyroid gland.

Pregnancy and lactation:

The drug is contraindicated for use during pregnancy and during breastfeeding.

Dosing and Administration:

The drug is taken orally before meals.

Immediately before use, 1-2 ml of purified or cooled boiled water is added to the contents of the vial.When shaken for 10 minutes, a uniform suspension should form.

With recurrent urogenital herpetic infection by schemes:

1) Every day, 6.0 mg (one vial, morning) once a day for 10 days;

2) Daily 6.0 mg twice a day for 5 days (intensive scheme, with severe immunosuppression, often recurrent forms of herpetic infection).

Further, maintenance therapy is prescribed at 6.0 mg every other day for 20 days.

Complex treatment includes the administration of the drug acyclovir according to the standard scheme of 200 mg five times a day for 5-10 days.

The course of treatment may vary depending on the severity of the condition and the severity of clinical symptoms.

Side effects:

In rare cases, there is an increase in temperature, allergic reactions: itching, rash, urticaria.

Overdose:

Cases of overdose were not observed.

When administered in a dose that exceeds the therapeutic dose by 40 times, the drug is able to cause minor hemodynamic changes in the intestine and kidneys, a mildly expressed leuko- and lymphopenic reaction, and affect the level of metabolic processes (may cause slight changes in the proportions of protein fractions of the blood).These violations are of a short-term, reversible nature and do not require additional arresting measures. Recovery can be accelerated by conducting a diuretic (furosemide) or infusion detoxification therapy.

Interaction:

In clinical use in combination with acyclovir, no interaction was found.

The interaction of sodium ribonucleate with other drugs has not been studied.

Special instructions:

With thyroid diseases, the drug should be administered under the supervision of an endocrinologist. When there are signs of thyroid dysfunction on the background of therapy, it is recommended to check the level of thyroid-stimulating hormone (TSH).

The use of the drug AKAVIA® does not prevent the transmission of the virus through sexual contact, therefore it is recommended to avoid sexual intercourse or use condoms when treating genital herpes.

Effect on the ability to drive transp. cf. and fur:

The use of the drug does not affect the ability to drive a vehicle or potentially dangerous mechanisms.

Form release / dosage:

Lyophilizate for the preparation of a suspension for oral administration, 6 mg.

Packaging:

By 290 mg (6.0 mg of active ingredient) in glass vials. The vials are hermetically sealed with rubber stoppers and crimped with aluminum caps; 5 vials per cell pack of PVC film; 1 pack of cells together with instructions for use in a cardboard pack.

Storage conditions:

Store in a dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

2 years.

Not applicable after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:LP-004071

Date of registration:10.01.2017

Expiration Date:10.01.2022

The owner of the registration certificate:VECTOR-MEDICA, CJSC VECTOR-MEDICA, CJSC Russia

Manufacturer: & nbsp

VECTOR-MEDICA, CJSC Russia

Representation: & nbspVECTOR-MEDICA CJSC VECTOR-MEDICA CJSC Russia

Information update date: & nbsp29.01.2017

Illustrated instructions

Instructions

Akavia® (Akaviya®)